🟢 PFE.BA is trading 0.6% up today after EU approval of bladder cancer treatment combo

PFE.BA is trading 0.6% up today at $9405 after the European Commission approved a new bladder cancer treatment combination co-developed by the company.

• The approval covers the use of the Keytruda and Padcev combination for patients with cisplatin‑ineligible resectable muscle‑invasive bladder cancer.
• Pfizer co-develops Padcev in partnership with Merck and Astellas, directly benefiting from this expanded regulatory clearance in the European market.
• Broader gains in U.S. markets are providing a supportive backdrop for the stock's upward movement.